TNF-α Inhibition: The Need for a Tumor Necrosis Factor Thermostat
- 1 June 2001
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 76 (6), 573-575
- https://doi.org/10.1016/s0025-6196(11)62405-1
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Fatal Sepsis in a Patient With Rheumatoid Arthritis Treated With EtanerceptMayo Clinic Proceedings, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Anticytokine Therapy — A New Era in the Treatment of Rheumatoid Arthritis?New England Journal of Medicine, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- ANTI-TUMOR NECROSIS FACTOR-α MONOCLONAL ANTIBODY THERAPY FOR RHEUMATOID ARTHRITISRheumatic Disease Clinics of North America, 1998
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinNew England Journal of Medicine, 1997
- The malarial fever response - pathogenesis, polymorphism and prospects for interventionPathogens and Global Health, 1997
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994